Mobius Therapeutics™ vision is to lead in ophthalmic perioperative pharmaceuticals. Our mission is to identify challenging needs and innovate solutions to improve patient care, patient access, and provider safety.
Glaucoma surgery is done in a highly regulated environment and new USP <800> standards bring more vigilance to the usage and disposal of hazardous drugs, like mitomycin C, in the ophthalmic surgical arena. Additionally, glaucoma surgery requires supplies to be state of the art, reliable, and readily available, so that the surgical suite can run like a well-oiled machine.
Fortunately, MITOSOL has it all.
Mobius Therapeutics™ offers the first and only FDA-approved ophthalmic formulation of MMC. Mitosol (mitomycin for solution) Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. It can be stored at room temperature for up to 24 months, is ready on demand and is reconstituted in a closed system that’s USP <800> compliant. In short, MITOSOL has created a new standard of care in glaucoma surgery.
Visit www.MobiusTherapeutics.com to learn more about our perioperative pharmaceutical franchise and our mission to improve the convenience, safety and integrity of perioperative pharmaceuticals for ophthalmic applications.
Mobius Therapeutics™, LLC
WMI-023 Rev 11/2019